SCHEMBL20725745

SCHEMBL20725745

C[C@@H]1CC(O)C(C(=O)OCc2ccccc2)(C(=O)OCc2ccccc2)C1

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
CYP17A1 P05093 2/20 0.44
CYP19A1 P11511 2/20 0.44
HTR2C P28335 1/20 0.43
DDB1 Q16531 1/20 0.42
CRBN Q96SW2 1/20 0.42
MAPK1 P28482 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32674103 0.82 ALDH1A1 (0.53) ALDH1A1CYP17A1CYP19A1HTR2CDDB1
SCHEMBL32674206 0.80 ALDH1A1 (0.50) ALDH1A1CYP17A1CYP19A1HTR2CDDB1
SCHEMBL25317306 0.80 ALDH1A1 (0.50) ALDH1A1CYP17A1CYP19A1HTR2CDDB1
SCHEMBL16865202 0.78 ALDH1A1 (0.49) ALDH1A1CYP17A1CYP19A1HTR2CDDB1
SCHEMBL31268160 0.77 ALDH1A1 (0.50) ALDH1A1HTR2CDDB1CRBNMAPK1
SCHEMBL25707989 0.75 ALDH1A1 (0.49) ALDH1A1HTR2CDDB1CRBNMAPK1
SCHEMBL4862689 0.75 SMN1; SMN2 (0.48) ALDH1A1HTR2CL3MBTL1KMT2ATSHR
SCHEMBL20461082 0.74 SMN1; SMN2 (0.52) HTR2CL3MBTL1KMT2A
SCHEMBL32674110 0.74 ALDH1A1 (0.50) ALDH1A1HTR2CDDB1CRBNMAPK1
SCHEMBL25213325 0.74 ALDH1A1 (0.46) ALDH1A1CYP17A1CYP19A1DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3227279-B1 1-OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS LILLY CO ELI (US) 2019-02-13 EP disclosed